Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Periprocedural use of tirofiban in elective percutaneous coronary intervention for long coronary lesions in stable patients with overlapping drug-eluting stents--the PETITION study: a prospective, randomized, multicenter study.
Zhang Q, Wang XL, Liao ML, Hu J, Yang ZK, Ding FH, Zhang JS, Du R, Zhu TQ, Shen WF, Zhang RY. Zhang Q, et al. Among authors: liao ml. Catheter Cardiovasc Interv. 2015 Mar;85 Suppl 1:762-9. doi: 10.1002/ccd.25864. Catheter Cardiovasc Interv. 2015. PMID: 25630513 Clinical Trial.
Absence of gender disparity in short-term clinical outcomes in patients with acute ST-segment elevation myocardial infarction undergoing sirolimus-eluting stent based primary coronary intervention: a report from Shanghai Acute Coronary Event (SACE) Registry.
Zhang Q, Qiu JP, Zhang RY, Li YG, He B, Jin HG, Zhang JF, Wang XL, Jiang L, Liao ML, Hu J, Shen WF. Zhang Q, et al. Among authors: liao ml. Chin Med J (Engl). 2010 Apr 5;123(7):782-8. Chin Med J (Engl). 2010. PMID: 20497664
One-year clinical outcome of interventionalist- versus patient-transfer strategies for primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results from the REVERSE-STEMI study.
Zhang Q, Zhang RY, Qiu JP, Zhang JF, Wang XL, Jiang L, Liao ML, Zhang JS, Hu J, Yang ZK, Shen WF. Zhang Q, et al. Among authors: liao ml. Circ Cardiovasc Qual Outcomes. 2011 May;4(3):355-62. doi: 10.1161/CIRCOUTCOMES.110.958785. Epub 2011 Apr 26. Circ Cardiovasc Qual Outcomes. 2011. PMID: 21521833 Clinical Trial.
Efficacy and safety of olmesartan medoxomil-amlodipine besylate tablet in Chinese patients with essential hypertension: A prospective, single-arm, multi-center, real-world study.
Cui Z, Qiu Z, Cheng W, Hu W, Ma G, Cai X, Jin Y, Zhao Y, He L, Li Y, Bu P, Chen X, Wang R, Chen L, Dong P, Feng L, Han X, Hong M, Hou Y, Liao M, Wang M, Wang X, Xie J, Xu Y, Wang Z, Huang K, Li Y, Li D, Ji X, Huang J, Wang J, Fang D, Wang J, Tang L, Liu Y, Fu G, Du J, Wang L, Liu M, Ge J. Cui Z, et al. J Clin Hypertens (Greenwich). 2024 Jan;26(1):5-16. doi: 10.1111/jch.14700. Epub 2023 Sep 4. J Clin Hypertens (Greenwich). 2024. PMID: 37667532 Free PMC article.
Efficacy and safety of olmesartan medoxomil‑amlodipine besylate tablets (Sevikar®) in older patients with essential hypertension: Subgroup analysis from the Sevikar study.
Cui Z, Qiu Z, Cheng W, Hu W, Ma G, Cai X, Jin Y, Zhao Y, He L, Li Y, Bu P, Chen X, Wang R, Chen L, Dong P, Feng L, Han X, Hong M, Hou Y, Liao M, Wang M, Wang X, Xie J, Xu Y, Wang Z, Huang K, Li Y, Li D, Ji X, Huang J, Wang J, Fang D, Wang J, Tang L, Liu Y, Fu G, Du J, Wang L, Liu M, Ge J. Cui Z, et al. Exp Ther Med. 2023 Dec 5;27(2):51. doi: 10.3892/etm.2023.12338. eCollection 2024 Feb. Exp Ther Med. 2023. PMID: 38234624 Free PMC article.
Mapping the potential for global offshore finfish mariculture.
Yu SE, Liao ML, Dong SL, Dong YW. Yu SE, et al. Among authors: liao ml. Mar Life Sci Technol. 2024 Nov 6;6(4):651-664. doi: 10.1007/s42995-024-00257-7. eCollection 2024 Nov. Mar Life Sci Technol. 2024. PMID: 39620091 Free article.
97 results